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Background: In Huntington’s disease (HD), the ratio between normal and mutant Huntingtin (polyQ-hHtt) is
crucial in the onset and progression of the disease. As a result, addition of normal Htt was shown to improve
polyQ-hHtt-induced defects. Therefore, we recently identified, within human Htt, a 23aa peptide (P42) that
prevents aggregation and polyQ-hHtt-induced phenotypes in HD Drosophila model. In this report, we evaluated
the therapeutic potential of P42 in a mammalian model of the disease, R6/2 mice.
Results: To this end, we developed an original strategy for P42 delivery, combining the properties of the cell
penetrating peptide TAT from HIV with a nanostructure-based drug delivery system (Aonys® technology), to form a
water-in-oil microemulsion (referred to as NP42T) allowing non-invasive per mucosal buccal/rectal administration of
P42. Using MALDI Imaging Mass Spectrometry, we verified the correct targeting of NP42T into the brain, after per
mucosal administration. We then evaluated the effects of NP42T in R6/2 mice. We found that P42 (and/or derivatives)
are delivered into the brain and target most of the cells, including the neurons of the striatum. Buccal/rectal daily
administrations of NP42T microemulsion allowed a clear improvement of behavioural HD-associated defects
(foot-clasping, rotarod and body weights), and of several histological markers (aggregation, astrogliosis or ventricular
areas) recorded on brain sections.
Conclusions: These data demonstrate that NP42T presents an unprecedented protective effect, and highlight a new
therapeutic strategy for HD, associating an efficient peptide with a powerful delivery technology.
Keywords: Huntington’s disease, Mouse model, Peptide, MicroemulsionIntroduction
Huntington’s Disease (HD) is a progressive neurodegenera-
tive disorder caused by an abnormal expansion of polyQ
(>35) domain in the N-terminus of the Huntingtin protein
(Htt) [1]. The worldwide prevalence of HD is 5–10 cases
per 100,000 persons. Currently, only symptomatic
treatments are available [2]. One of the histopathological
marker of HD is intranuclear aggregates formed by the
polyQ-mutated Htt protein. These insoluble structures
trap crucial proteins [3-5] and can physically block cellular
traffic [6-8] and alter for instance the ubiquitin-proteasome
degradation process [9,10]. Altogether these defects finally* Correspondence: florence.maschat@igf.cnrs.fr
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unless otherwise stated.contribute to the neurodegeneration occurring primarily in
the striatum and involving other brain areas at later stages
of the disease.
Although it is well established that the disease onset
occurs as a consequence of expanded polyQ, other
domains of Htt could also influence the pathogenicity
of polyQ-hHtt. Indeed, the first 17 amino acids (N17
region) and the proline-rich region (PRR region), both
flanking the polyQ stretch were found to influence
aggregation [11,12].
Most research undertaken to find a cure for HD focus
on the mutated allele (trying to reduce its expression)
[13], or on the polyQ stretch that is responsible for
aggregation, but that is also present in other neurodegen-
erative diseases [14,15]. Our approach is based on the
observation that the ratio between normal and mutantLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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of the disease [1,16-22]. In a previous work, we confirmed
the protective role of wild-type N-terminus Htt [22]. We
further screened human hHtt, for peptides able to prevent
polyQ-hHtt aggregation in HeLa cells. To this end, 548aa
N-terminal part of hHtt has been fragmented in shorter
fragments according to domains lying in the protein.
This step-by-step approach allowed the identification
of a 23aa peptide (P42), lying in the N-terminus (position
480–502 aa) of normal human Htt (hHtt), able to prevent
aggregation in cellulo in HeLa cells, and to retain protective
properties on different phenotypes induced by the
expression of the polyQ-Htt in vivo in a Drosophila
model of HD (on eye degeneration, axonal trafficking
and larval locomotion for instance) [8]. P42 is able to
prevent eye degeneration of flies expressing hHtt exon1
(covering 67aa, but not P42) with expanded polyQ [8].
Interestingly, this effect of P42 is specific of HD, and not
of other polyQ-induced diseases [8]. This showed that P42
is able to act through hHtt 67 aa exon 1, independently to
the polyQ stretch.
These previous data suggested that P42 could represent
a new therapeutic agent to specifically target HD
hallmarks. To test this possibility, we decided to analyse
P42 protective properties in another model of HD,
preferentially mammalian. In order to better quantify
the protective power of P42, we choose to test R6/2
mice that express, as in the fly model, exon1 of human
Huntingtin bearing 144 CAG repeats, and which do not
contain the P42 domain [23,24]. These mice exhibit early
and severe behavioural phenotypes, associated to histo-
logical biomarkers mimicking HD. Symptoms start very
early at week 5, leading to a premature death in weeks
12–15. In particular, R6/2 mice present neuroanatomical
abnormalities including progressive reduction of the brain
volume. They are also characterized by the presence of
widespread nuclear inclusions of mutant polyQ-Htt in
brain neurons. In addition, behavioural abnormalities are
also present, including loss of coordination [25].
In order to test P42 in R6/2 mice, we developed a new
peptide-based strategy. Peptides have many therapeutic
applications, principally due to their efficiency, their
selectivity and a high specificity compared to other
molecules. Another important advantage concerns their
degradation in amino acids that present a low risk of
toxicity. Nevertheless, peptides present some limitations,
related to their low capability to cross membrane barriers,
short half-life, and difficulties of administration. To
overcome these problems and optimize the delivery and
action of P42, we adapted two complementary and
original strategies. First, in order to cross cell membrane
barriers efficiently and reach cytoplasmic and nucleic
compartments, we fused P42 to the protein transduction
domain of TAT from HIV. This 11aa Cell PenetratingPeptide (CPP) can be efficiently used as a vehicle to deliver
fused peptides into living cells [26,27], via endocytosis
[28]. We first tested P42-TAT fusion peptide in HeLa
cells for its abilities to transduce cells, and to rescue
polyQ-hHtt aggregation. Secondly, in order to optimize
the pharmacokinetic characteristics of P42 (serum half life
and distribution profile) and to provide a non-invasive
route for repetitive delivery of this fusion peptide, we used
a novel water-in-oil microemulsion drug delivery vector
named Aonys® [29,30]. Aonys® provides a transmucosal
(buccal) route of administration and enhances CNS
penetration, which we verified by MALDI Imaging Mass
Spectrometry.
The Aonys® formulated fusion peptide (named NP42T)
represents a new product that combines for the first time
the properties of a CPP, with a nanostructure-based drug
delivery system. The aim of this study was to evaluate the
efficacy of this new formulation of P42, NP42T, in the
mammalian R6/2 HD mouse model.
Despite the high aggressiveness and the rapid onset of
the phenotypes in the R6/2 model, buccal/rectal adminis-
tration of NP42T significantly improved motor, histological
and molecular phenotypes. These studies allowed to
divert the natural properties of a Huntingtin domain
P42 towards protection against aggregation and toxicity,
which represents a new approach to fight against HD.
Materials and methods
Peptide synthesis and formulation
To ensure P42 diffusion, we designed a fusion peptide
where P42 was conjugated to the 11aa TAT Cell Penetrating
Peptide (CPP). The peptide P42-TAT (AASSGVSTPG
SAGHDIITEQPRS-GG-YGRKKRRQRRR) was synthetized
and purified by Millegen company (France) with either a
TAMRA (Tetra-Methyl-Rhodamine) tag at N-terminal
position, or without any tag. NP42T is based on Aonys®
drug delivery vector [29,30] where P42-TAT has been
incorporated in a water-in-oil microemulsion. The
lipid mixture Aonys® was prepared extemporaneously by
weighing the lipid constituants. The appropriate amount
of the peptide P42 powder (Millegen, purity >95%) was
dissolved in MilliQ water. At a well-defined ratio, the
P42TAT-Aonys® lipid monophasic microemulsion forms
rapidly by short vortex mixing of the lipid mixture with
the aqueous peptide solution.
Cell culture experiments and filter retardation assays
HeLa cells were grown and maintained in DMEM
medium (Gibco) supplemented with 10% fetal calf serum
and glutamine. HeLa cells were grown in 6 well plates,
and pDdest53-GFP-hHtt171aa-136Q (0.75 μg) was trans-
fected with JetPei reagent (Qbiogene). Equal amounts of
pcDNA-Cherry-P42 or control vector were added for each
transfection to level the total amount of plasmid DNA. To
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TAMRA-P42-TAT was added at the same time as
pDest53-GFP-hHtt171aa-Q136 transfection, at different
concentrations (0, 0.5, 1, 5, 10 or 20 μM). Cells were incu-
bated with plasmid and peptide for 12 h. Then the medium
was washed twice with PBS, the cells trypsinized, and grown
on a coverslip with new DMEM medium for 6 h. This step
was necessary to eliminate the peptide that crystallizes on
the well. Eventually, cells were fixed with 4% paraformalde-
hyde and immunostained for microscopic analysis. To
observe the internalization of the peptide TAMRA-
P42-TAT, the signal was amplified by anti-TAMRA immu-
nostaining (1:500- Invitrogen). Nuclei were counterstained
with DAPI (4′, 6 diamino-2-phenylindole). The pictures
were taken with a confocal laser scanning microscope
model LSM780 (Carl Zeiss).
For filter retardation assays, protein extracts from
HeLa cells were performed according to [31], with the
following modifications: After transfection, HeLa cell
pellets were treated by DNase and resuspended in
150 μl of 1% SDS and 50 mM DTT in PBS. The sam-
ples were boiled for 5 min, and diluted with 150 μl
of 1% SDS. For each sample, two aliquots of 150 μl
were filtered through a cellulose acetate membrane
(0.2 μm pore size, Schleicher & Schuell), using a Bio-Rad
dot-blot filtration unit. Membranes were then immuno-
detected with anti-GFP primary antibody (rabbit
polyclonal (1:6000) Invitrogen), as indicated. The
membranes have been secondary detected by HRP
conjugated anti-rabbit antibody (1:50000-Jackson).
Immunoreactive spots were detected with Immuno-Star
WesternC kit (Bio-Rad), and quantifications have been
performed with Image Lab3.0 software.
Pharmacokinetics
To test the stability of the peptide in the brain, single
intracerebroventricular (ICV) injection of peptides was
performed in the right ventricle of C57BL/6 mice as
described in [15]. 5 μg or 1 μg of TAMRA-P42-TAT
were stereotaxically injected into the right lateral
ventricle (coordinates 1 mm right lateral to bregma
and 3 mm ventral to the skull surface) of C57BL/6 J
mice using a 10 μl Hamilton syringe at a rate of
0.2 μl to 1 μl/min. As a control, saline was injected in the
same volume and at the same rate. Mice were sacrificed at
6 h or 24 h by transcardiac perfusion of PFA.
For MALDI analysis, wild-type C57BL/6 J mice have
been injected either by ICV (2.1 μg), or treated with
empty NP, or with NP42T (210 μg) microemulsions.
For NP and NP42T, four buccal and four rectal
administrations (1 ml/kg) have been performed, spaced by
30 minutes to ensure mucosa internalization. Two mice
have been treated for each condition and sacrificed 3 h
after the injections.Mass spectrometry and MALDI Imaging Mass
spectrometry (IMS)
MALDI MS and MS/MS analysis: Spectra acquisition has
been performed using the 4800 Plus MALDI TOF/TOFTM
mass spectrometer (ABSciex) controlled by the 4000
Series ExplorerTM. MS spectra were acquired in a reflector
positive mode (mass range: m/z 700–4000, laser intensity
set at 50% and 3000 total laser shots per spectrum,
MS resolution ≥ 12000–17000). MS/MS precursor was
selected manually with an absolute mass window of
1 Da and each MS/MS spectrum is the result of 1000
total laser shots with a laser intensity set at 50% and a
MS/MS resolution ≥ 2000–5000. The fragmentation was
performed at collision energy of 2 kV and a collision air
pressure set at 10−6 Torr.
Tissue preparation and MALDI imaging analysis:
Frozen brain sections were cut in 15 μm slices using
an HM 550 OVPD cryostat (Fisher Scientific, Illkirch,
France), set at −20°C, mounted on ITO coated conductive
glass slides and allowed to thaw and desiccate in a vacuum
desiccator. Tissue sections were then coated manually with
a 10 mg/ml α-cyano-4-hydroxycinnamic acid dissolved
in 50% acetonitrile (ACN) and 0.1% trifluoroacetic
acid (TFA).
MALDI imaging was performed using the 4800 Plus
MALDI TOF/TOFTM Analyzer (AB Sciex). Image
acquisition was achieved using the 4800 imaging tool
software (MSI imaging). Imaging of brain sections
was performed in a reflector positive mode, in the
mass range of m/z 500–4000, with a resolution of
50 μm in a 100 × 100 μm raster, and laser intensity
set at 80% of full laser intensity as selected within the
4000 Series ExplorerTM. At each position of the tissue
section, an averaged mass spectrum is generated from
1000 consecutive laser shots.
The two dimensional ion image of the tissue section
was analyzed using Tissue ViewTM software (Applied
Biosystems/MDS analytical technologies). A colour
scale representing signal intensity is exported from
Tissue ViewTM software to provide semi quantitative
information.
R6/2 transgenic and wild-type mice
R6/2 mouse model, based on the expression of the
polyQ expanded human exon1 is a well-characterized
model showing early and strong symptoms and leading
to a premature death at 3 months of age [23-25].
Initially, heterozygous R6/2 males were obtained from
Jackson Laboratory (stock 006494). The crossing of these
R6/2 males with C57BL/6-CBA F1 females generated
the animals used in this study. The pups were weaned at
week 3. After the weaning, the pups were housed in
groups of mixed genotypes, and data were recorded for
each mouse. Females issued from this crossing were
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the tremor or clasping behaviour, transgenic mice could
not be distinguished from normal mice in their home
cage. The experimenters were blind to the genotype of
the mice until the end of the protocol. The mice were
housed fifteen per cage under standard conditions
with ad libitum access to water and food. At the end
of the protocol, mice were genotyped by PCR using
tail-tip DNA as described [23]. A real time PCR was
performed with the following primers HDexon1 Forward :
5′- CGG CTG AGG CAG CAG CGG CTG T-3′, and
HDexon1-Reverse : 5′- GCA GCA GCA GCA GCA ACA
GCC GCC ACC GCC3′. At week 11, mice were sacrificed
and tissues fixed for histology by transcardiac perfusion of
4% PFA in PBS.
P42 treatment
Procedures for the care and treatment of animals
were carried out according to CNRS guidelines, and the
experimental protocol was approved by the institutional
animal care committee of the Institut de Génomique
Fonctionnelle, in accordance with directives of the French
Ministry of Agriculture (agreement number: D34-172-13).
For animal experimentation, a cohort of 30 females was
divided into four groups (WT treated with empty NP
(n = 5); WT treated with NP42T (n = 8); R6/2 treated
with empty NP (n = 8); R6/2 treated with NP42T (n = 9)).
Administrations were performed five days a week, at the
same time of the day, starting in 2-week-old mice. The
treatment was performed until the mice were sacrificed
(at week 11). NP42T peptide (600 μg/ml/kg) was adminis-
trated twice a day per mucosa, with two buccal injections
until the mice were 4 week old, and via rectal and buccal
injections for older animals older.
Behavioural tests of mice
Body weights of the R6/2 transgenic and wild-type mice
were recorded weekly at the same time of the day, from
the week 2 [14].
Motor performance was assessed using an accelerating
rotarod (Stoelting, Ugo Basile, Biological Research
apparatus, Varese, Italy), at weeks 6, 8, and 10 [14].
On the first day, the mice were trained with a trial at an
accelerating velocity from 4.5 to 40 rpm. Subsequently,
two trials were performed during two consecutive days. In
each trial, mice were placed onto the rotarod at a constant
speed of 4.5 rpm for 5 seconds, which then accelerated at
a constant rate up until 40 rpm, for a maximum of 5 min.
The daily trial was composed of two sessions of 5 min
separated by 20 min. The latency to fall from the rotarod
was recorded every day for each mouse, and the average
of two trials was used for statistical analysis.
For the clasping test, mice were suspended by the tail
for 30 sec. The frequency and the duration of the foot-clasping posture were scored twice a week [32]. The
average of two trials was used for statistical analysis. The
tests were performed at 7, 9, and 11 weeks of age.
Statistical tests
For tests with a single time point of data acquired, either
an unpaired t-test or one way ANOVA, followed by
Fisher’s LSD post hoc test was used, when necessary.
Otherwise two-way ANOVA ordinary with Time and
Group or Genotype and Treatment as between-subject
factors was applied, followed by Bonferroni’s post-hoc
analysis for multiple comparisons. In all cases, significance
threshold was set at p < 0.05. Prism 6.0 software was used
to perform statistical analyses.
Immunohistochemistry
Coronal brain sections of 50 μm thickness were cut with
an electronic microtome (Microm HM 650 V). The
slides from bregma −0.60 to bregma −0.80 mm were
used for Hematoxylin/eosin staining and immuno-
stained with monoclonal antibody anti-Huntingtin
(MAB5374 – Millipore – 1:1000) or polyclonal anti-GFAP
(AB5804 – Millipore – 1:1000 [33]). For each animal,
systematic pictures were taken with the slide scanner
Hamamatsu nanozoomer. The areas of lateral ventricles
and cortex thickness were measured with NDP software
(Nanozoomer Digital Pathology Virtual SlideViewer).
Quantifications of aggregates number and size, or
GFAP signal, were scored with ImageJ software from
256 μm × 256 μm images. Representative pictures for
these immunostainings obtained with the confocal
laser scanning microscope model LSM780 (Carl Zeiss)
are shown.
TAMRA-P42-TAT injected mice were also immuno-
stained with rabbit monoclonal anti-DARPP32 (MAb2306 -
Cell Signaling Technology - 1: 1600), secondary detected by
Alexa 488 anti-rabbit (1: 2000) to label the striatum, and
with mouse monoclonal anti-NeuN (MAB377 – Millipore -
1: 1000), secondary detected by Dye light blue anti-mouse
(1: 500), as a neuronal marker.
Results
Construction of NP42T, a new tool against HD
Intracellular delivery of P42 peptide when conjugated with TAT
In order to ensure P42 diffusion, we designed a fusion
peptide encompassing P42 conjugated to the 11aa
TAT Cell Penetrating Peptide (CPP). TAT-conjugated
peptides can cross the blood–brain barrier and plasma
membranes [28,34]. We first validated the effectiveness
of the P42-TAT peptide on polyQ-hHtt aggregation. To
this end, HeLa cells were simultaneously transfected
with vectors expressing GFP-hHtt171aa-Q136 and different
forms of the peptide: Cherry-P42 (Figure 1B-B”) or Cherry-
P42-TAT (Figure 1C-C”), compared to GFP-hHtt171aa-Q136
Figure 1 (See legend on next page.)
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Figure 1 P42-TAT inhibits efficiently polyQ-hHtt aggregation. HeLa cells were transfected with GFP-138Q-hHtt171aa (detected in green), in
the presence of: BS empty vector (A, A’, A”); Cherry-P42 (B, B’, B”); Cherry-P42-TAT (C, C’, C”); or TAMRA-P42-TAT (D, D’, D”). Cherry and TAMRA
are detected in red. As Cherry-P42 (B), Cherry-P42-TAT (C) is present both in the cytoplasm and in the nucleus (visualised by DAPI, in blue). The
synthetic peptide TAMRA-P42-TAT provided in the culture medium is internalized into the cells and form vesicles (D). The delivery of P42-TAT
inhibits aggregation (C’, D’), as does P42 (B’), to compare to A’. (E) Filter retardation assays were performed on transfected cells in presence of
increasing amounts of P42-TAT (0.1, 1.5, 1, 5, 10 or 20 μM) delivered into the medium. A representative dot blot, where GFP is monitored, is
shown. Quantification was performed by Image J on 3 independent experiments and is reported on a graph, with respect to the control (BS)
set up at 100%. As a control, quantification of cells co-transfected by GFP-138Q-hHtt171aa and Cherry-P42-TAT is shown (P42-TAT). Data represent
means +/−SEM, and were analysed using Student’s t. test (*** p < 0,001).
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P42-TAT is able to completely rescue the GFP-Htt171aa-
Q136 aggregation, as did P42 alone (Figure 1B’ , C’). We
further tested the ability of exogenous P42-TAT to
transduce HeLa cells when provided into the culture
medium. To this end, we used a synthetic TAMRA
end-labelled version of P42-TAT to follow its entry
into cultured cells (Figure 1D-D”). As shown on Figure 1D,
TAMRA-P42-TAT was taken up by almost all the
cells and was concentrated into small vesicles. These
data confirmed the high efficiency of transduction of
the fusion peptide. We then investigated the ability of
TAMRA-P42-TAT to prevent aggregate formation,
when provided into the culture medium (Figure 1E).
Increasing concentrations of TAMRA-P42-TAT syn-
thetic peptide (from 0.1 μM to 20 μM) drove a clear
dose–response effect with a complete inhibition of
aggregation in presence of 10 μM peptide. Note that even
a 20-fold excess of this protective dose only produced 25%
mortality, as assessed by the MTT test [35], while the IC50
value could not be measured (data not shown). Altogether
these data confirm the protective activity of the P42 peptide
even in the presence of TAT.
Pharmacokinetics and targeting of P42-TAT into the brain
One challenge to use P42-TAT at therapeutic ends was
to find a non-invasive route of delivery, such as buccal
administration and to improve P42-TAT bioavailability
and uptake into the brain. To this end, we developed
a nanostructure-based drug delivery system (Aonys®
technology), to form a water-in-oil microemulsion (referred
to as NP42T) allowing per mucosal buccal/rectal ad-
ministration, and compared this mode of delivery to
intra-cerebroventricular (ICV) injection.
We first analysed P42-TAT degradation in brain extracts
at different times of incubation (0, 1, 3 and 6 h) by mass
spectrometry. We used MALDI technique to analyse
the composition and structure of biological molecules
present in solution. In these conditions, full length
P42-TAT was degraded within 1 hour, and shorter
peptides were detectable by mass spectrometry at
3 hours (Figure 2A). The mass of these products was
compared with that of peptides generated by “insilico” degradation and 30 masses corresponding to
potential peptides were issued from the original P42-TAT.
We hypothesized that some of these degradation
products could be present in the brain in addition to
the parent P42-TAT peptide. Thus, we analysed the fate of
P42-TAT when administered into the brain of wild-type
C57BL/6 J mice by ICV injection or by buccal/rectal
administration of NP42T encapsulated into Aonys®
microemulsion. Since the brain corresponds to approxi-
mately 1% of the mouse total weight, we used 100 times
more NP42T than for ICV injection.
We used MALDI Imaging Mass Spectrometry [36],
whereby the different compounds present in brain sections
can be detected simultaneously without further labelling.
Using this technology, intact P42-TAT peptide and its
degradation products were sought into mouse brain slices
three hours after injection. An analysis of the distribution
of 30 putative peptide derivatives was performed on
brain sections of treated mice. This extensive analysis
allowed identifying P42-TAT derivatives only detected in
P42-TAT treated mice (Figure 2B). For instance one
peptide (m/z 1801.84) is detected in brain extracts
after 1 or 3 hours incubation (Figure 2A). A MS/MS
characterisation of this peptide confirmed that it corre-
sponds to a part of injected P42-TAT: −GSAGHDII
TEQPRSGGYG (Additional file 1: Figure S1).
These data confirm that P42-TAT is able to reach the
brain when administrated via Aonys® microemulsion.
Targeting of the peptide in neuronal cells of the striatum
To ensure its function and effectiveness in vivo, it was
important to test the distribution of P42-TAT. To this
end, we tested the spreading of a TAMRA-P42-TAT pep-
tide in brains of wild-type C57BL/6 J mice, administrated
by intra-cerebroventricular (ICV) injection. Mice were
sacrificed 3 hours after injection, and brain sections
analysed. On injected-brain sections, vesicles containing
the peptide were detectable within the cells and in
the ipsilateral and controlateral brain areas from the
injection site, including the cortex and the striatum
(Additional file 1: Figure S2). We identified that in the
striatum, TAMRA-P42-TAT was largely diffusing within
the neurons, including medium-size spiny neurons
Figure 2 Pharmacokinetics of P42-TAT in the brain. A- MALDI-MS analysis (ranging from 699 to 4013 m/z) of mice brain soluble extract before
(control), immediately (t0), or after 1 hour (t1h) and 3 hours (t3h) of incubation with 15 μg of P42-TAT peptide. Entire P42-TAT corresponds to m/z
3879.95 at t0. A m/z 1801.84 derivative is detected at t1h and t3h (*) B- The distribution of 30 P42-TAT putative derivatives selected have been
analysed after IMS and TissueView processing from wild-type mice injected by ICV, or treated with empty NP, or with NP42T microemulsions, as
indicated. This allowed to identify one major product, visualized on the brain section image and on the graph (ranging from 1796 to 1808 m/z).
Red dot corresponds to the m/z 1801.84 derivative of P42, suggesting that this product is still present in the brain, 3 hrs after the Aonys® administration.
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be visualized in the different cellular compartments,
nucleus and cytoplasm. Whereas P42-TAT could be
detected in different neuronal populations (NeuN cells
Figure 3) or cilia cells (Additional file 1: Figure S2), but
also in astrocytes (data not shown), we could not identify
a preferential targeting.
Altogether these data showed that P42-TAT has the
ability to diffuse into the brain in the different cell
layers, including the striatum. It is also able to reach the
different subcellular structures (nucleus and cytoplasm) of
the neurons. We also showed that delivering the peptide
using Aonys® water-in-oil microemulsion via buccal/rectal
mucosa guarantees the peptide to reach different parts
of the brain, as efficiently as by intracerebroventricular
injection.
Treatment of R6/2 mice by NP42T
In order to confirm in vivo the efficiency of P42 combin-
ation with TAT and the Aonys® microemulsion, we tested
the effect of NP42T in R6/2 mouse model of HD. R6/2
mice are a particularly suitable model for two reasons: first,
P42 protective properties have been tested in a Drosophila
model, expressing exon1 [8], and it was important to testTAMRA-P42-TAT Anti-DA
10 m 
10 m 
Figure 3 TAMRA-P42-TAT distribution in the striatum. TAMRA-P42-TAT
striatum in DARPP32 positive cells (in green). These cells are also NeuN pos
the nucleus and the cytoplasm.this peptide on a mammalian equivalent model. Second,
in R6/2 mice, the P42 domain is lacking, allowing to
precisely seizing the protective properties of exogenously
administered P42.
R6/2 mice suffer from a progressive decrease in body
weight and resting tremor, movements described as
resembling chorea [23,24]. Administrations of P42-TAT/
Aonys® (NP42T) or empty (NP) microemulsions via
buccal and/or rectal mucosa were performed daily, 5 days
per week, in R6/2 and in wild-type C57BL/6 J mice.
NP42T was administrated between week 2 and week
11: twice orally during the first two weeks and orally
plus rectally from week 4 to week 11. Several polyQ-hHtt
behavioural associated defects were analysed (foot-clasping,
rotarod or body weights), and several markers were
evaluated on brain sections (size of ventricles, aggregation
and astrogliosis).
NP42T reduces behavioural defects of R6/2 mice
To evaluate the therapeutic potential of P42-TAT, we
analysed different behaviours.
When suspended by the tail, normal mice spread their
four limbs, whereas R6/2 mice clasp their hind- andAnti-NeuN RPP32 
10 m 
(in red) was injected by ICV in wild-type mice, and is detectable in the
itive neurons (in blue). Note that TAMRA-P42-TAT is visualized both in
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(Figure 4A, A’). Six-week-old R6/2 animals begin to
exhibit this clasping reflex, which can be easily used toFigure 4 Aonys® NP42T treatment ameliorates behavioural deficits in R
absent in WT littermates (A). (B). Only groups treated with NP42T show a clea
(F(Genotype x Treatment)1,25 = 6.4, p = 0.0179). Post-hoc comparison (Bonferro
R6/2 (NP42T), with two way ANOVA (F(Group x Time)6,78 = 1.0, p = 0.4022) sim
mice treated with NP42T or with empty NP (placebo) at 6, 8 and 10 weeks of
Beneficial effect is observed for R6/2 treated with NP42T: Two way ANOVA (F
the four groups of mice was different over time. Post-hoc comparison (Bonfe
8wks ***p < 0.001 WT (NP) vs R6/2 (NP); *p < 0.05 R6/2 (NP) vs R6/2 (NP42T); 10w
(D) Body weight of R6/2 mice is recovered by both early and late administration
mice, treated with empty NP (placebo) or with NP42T. Graphs represent the bod
NP42T inverts the curves and restores a gain of weight in pre-symptomatic. One
**p < 0.01 WT (NP) vs R6/2 (NP); **p < 0.01 R6/2 (NP) vs R6/2 (NP42T). Data represeexamine novel treatments. We first assessed the effect
of buccal mucosa administration of NP42T on foot
clasping (Figure 4B). The duration of clasping posture6/2 mice. (A) R6/2 mice present a foot-clasping behaviour (A’)
r inhibition of clasping duration at 11wks: Two way ANOVA
ni’s test): **p < 0.01 WT (NP) vs R6/2 (NP); **p < 0.01 R6/2 (NP) vs
ilar over time. (C) Rotarod performances of wild-type (WT) or R6/2
age. Motor deficit is identified in R6/2 mice already at week6.
(group x time)6,78 = 2.362, p < 0.05) indicates that rotarod deficit of
rroni’s test): 6wks *p < 0.05 R6/2 (NP) vs R6/2 (NP42T); *p < 0.05;
ks ***p < 0.001 WT (NP) vs R6/2 (NP); ns R6/2 (NP) vs R6/2 (NP42T).
s of NP42T. Body weight variations were measured in WT and R6/2
y weight evolution from 8wks to 11wks in percentage. In HD mice,
way ANOVA: (F(3,24) = 5.2, p < 0.01). Post-hoc comparison (Fisher’s LSD):
nt means +/−SEM (n = 5-9 per group).
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R6/2 mice, with a mean score of 13.7 ± 4.27 s in 11
week-old animals. NP42T treatment reduced massively
this defect, with a 10 fold better score, showing a clasping
duration of 1.35 ± 0.71 s in 11 week-old R6/2 mice
(Figure 4B), which was indistinguishable from the
wild-type score. Therefore, NP42T treatment clearly
prevents hindleg reflex with a durable effect.
Around the same age, R6/2 mice also begin to
display other gradual changes in motor function
such as stereotypical hindlimb grooming, and the
emergence of some involuntary movements. As a
result, their motor coordination progressively
deteriorates, which can be detected as a reduction
in the time they can stay on a rotating rod, the
so-called Rotarod. Thus, using the rotarod test,
we analysed motor coordination and balance
performance of R6/2 mice treated with NP42T or
empty NP (Figure 4C). Rotarod capacities were
tested from week 6, when R6/2 mice begin to
present motor defects. At that time, R6/2 mice,
which had already been treated for 4 weeks with
NP42T, presented normal motor performance
(249 ± 9.7 s) similarly to wild-type littermates
(234.6 ± 15.9 s). On the other hand, placebo-treated
R6/2 mice showed significantly lower motor
performances (172.5 ± 13.82 s) (Figure 4C). The
NP42T early and chronic treatments allowed a delay
of motor defects onset in a sustained manner. Ten
week-old NP42T-treated R6/2 animals presented a
lower score (146.83 ± 12.69 s) compared to wild-type
mice treated with empty NP (placebo) or NP42T
(respectively 269.75 ± 9.69 s and 248.72 ± 10.59 s),
but maintained an important advantage compared to
placebo-treated R6/2 mice (97 ± 8.56 s). In the
presence of NP42T, motor deficits were delayed by
approximately 4 weeks (Figure 4C).
These results show that NP42T is able to significantly
rescue behavioural dysfunctions of R6/2 when using
chronic administrations.
NP42T impacts peripheral phenotypes
The Aonys® formulation technology allows the delivery
of the therapeutic peptide NP42T via the lymphatic
system and general circulation to the central nervous
system as well as to other organs. Indeed, peripheral
symptoms have an important impact on HD patient
survival. Cardiac dysfunctions and diabetic anomalies
contribute to HD patient mortality [37]. Among peripheral
phenotypes, one of the major defects leads to an alteration
of the body weight evolution. Indeed, R6/2 mice
begin to lose weight at week 8 (Figure 4D). Between
week 8 and 11, wild-type cohorts exhibited a bodyweight gain of 5.47% ± 1.1. During the same time
period, placebo-treated R6/2 animals showed a weight
loss of −3.39% ± 2.1, whereas NP42T-treated R6/2
mice exhibited an increase of 3.92% ± 1.61 of their
mean body weight. These results showed that NP42T
was able to restore the body mass curve (Figure 4D).
NP42T reduces histopathological markers of HD in R6/2
mice brains
R6/2 brains are characterized by an atrophy of the neostria-
tum [24]. When 11 week-old, mice do present an abnormal
organisation of the brain, with a clear enlargement of the
ventricles (Figure 5A). To investigate whether the NP42T
peptide was able to prevent structural changes observed in
this HD model, mice brain sections were prepared and
lateral ventricle area measured (Figure 5). Ventricle enlarge-
ment in R6/2 is at the expense of the striatum area, and of
the cortex [38]. At week 11, R6/2 striatum and cortical
thickness were only slightly affected compared to wild-type
(Rattray et al., [24]) that were not significantly recoved by
NP42T (data not shown). A clear rescue was however
observed on lateral ventricle enlargement (Figure 5).
NP42T-treated R6/2 mice exhibited a mean ventricle
area of 0.468 ± 0.06 mm2 (Figure 5B), similar to wild-type
animals 0.306 ± 0.07 mm2 (not shown), whereas placebo-
treated R6/2 mice presented a significant enlargement of
the ventricles with a mean area of 0.745 ± 0.1 mm2
(Figure 5A).
Loss of brain volume in HD is also accompanied by a
significant increase in astrocyte number, as shown when
using a specific immune-marker GFAP (Figure 6A). We
further analysed the astrogliosis process and identified
that NP42T lowers the number of astrocytes in the
brain cortex (Figure 6B) (with the mean GFAP signal of
196 ± 40 for NP42T-treated mice compared to 272 ± 36 for
placebo-treated mice) (Figure 6C) and in the striatum (with
the mean GFAP signal of 171 ± 28 in NP42T versus
239 ± 41 in placebo-treated R6/2 cohorts (Figure 6D),
which correlates with a rescue of the brain volumes in
NP42T-treated mice, as compared to placebo treatment
(Figure 5).
Finally, to determine whether NP42T was able to
target the mutant polyQ-hHtt aggregates present in
R6/2 mice, as shown in HD Drosophila model, we
monitored both the number and the size of these nuclear
inclusions (Figure 7A-A’ , B-B’). After quantification,
(Figure 7C-F) we found that aggregates were still
present in R6/2 mice treated by NP42T, both in the
striatum and the cortex. The number of aggregates
was significantly reduced by 50% in both the striatum and
the cortex in NP42T-treated R6/2 mice (Figure 7C-D).
In contrast, the size of the remaining aggregates
remained unchanged in both the cortex and the striatum
(Figure 7E-F).
Figure 5 NP42T delivery reduces ventricle enlargements in R6/2 mice. (A, B) brain sections of 11wks R6/2 mice treated with empty NP from 9wks to
11wks (A), or with NP42T (B) (scale from 0 to 8 mm) with enlargements shown (scale from 0 to 1 mm). Brain sections have been selected with the slide
scanner Nanozoomer Hamatsu, and correspond to −0,6 or −0,8 mm bregma point. In presence of NP42T, the ventricle size is closed to WT. (C) R6/2 and
WT mice were treated with empty NP (−) or with NP42T from 2wks to 11wks. Data represent means +/−SEM (n = 4-8 per group), and were analysed using
one way ANOVA: (F(3,18) = 6.4, p < 0.01). Post-hoc comparison (Fisher’s LSD): **p < 0.01 WT (NP) vs R6/2 (NP); *p < 0.05 R6/2 (NP) vs R6/2 (NP42T).
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effect of P42 in vivo. The original delivery method based on
CPP and a novel microemulsion formulation allowed the
peptide to efficiently cross the blood–brain-barrier and its
wide spread into the brain, with an efficient rescue on most
of the associated HD-phenotypes that were tested.
Discussion
Despite of recent progresses, HD remains a fatal neuro-
degenerative disorder. In this context, the identificationof P42 represents a new therapeutic avenue. P42 is a
23aa peptide that lays in the N-terminal sequence of
Huntingtin. We previously showed that this peptide
is able to prevent aggregation of mutant Huntingtin in
HeLa cells. Its therapeutic potential was also confirmed
in vivo in Drosophila models of HD, on different
phenotypes specifically induced by the expression of
polyQ-hHtt [8]. To confirm P42 protective properties, we
choose in this report to test P42 in a mammalian animal
model.
Figure 6 NP42T delivery reduces astrogliosis in R6/2 mice. R6/2 mice treated with placebo present an important GFAP positive astrogliosis in
the cortex (A) and in the striatum (not shown). R6/2 mice treated with NP42T present lower GFAP positive astrogliosis in the cortex (B) and in
the striatum (not shown). Pictures were obtained by laser confocal microscopy (Zeiss LSM 780). The quantification shows that NP42T reduces
astrogliosis in the cortex (C) and the striatum (D), but the recovery is not significant. Data represent means +/−SEM (n = 4-7 per group), and were
analysed using one way ANOVA: GFAP in the cortex (F(3,19) = 4.9, p < 0.01) and GFAP in the striatum (F(3,18) = 6.1, p < 0.05). Post-hoc comparison
(Fisher’s LSD): **p < 0.01 WT (NP) vs R6/2 (NP); ns R6/2 (NP) vs R6/2 (NP42T) in the cortex and *p < 0.05 WT (NP) vs R6/2 (NP); ns R6/2 (NP) vs R6/2
(NP42T) in the striatum.
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ability to deliver this peptide into the brain. Indeed poor
absorption and high enzymatic degradation of peptides
are critical for the use of such tools. The need for a
chronic treatment requires the development of a
non-invasive method of administration, in order to
ensure patient compliance. To this end, we joined for the
first time two original strategies to provide an efficient
distribution of P42 until its targeting into the cells,
by using i) Aonys®, a water-in-oil microemulsion
[29,30] and ii) a fusion peptide composed of TAT andits cargo P42. We verified that the presence of TAT
enhances the diffusion of P42 into a large number of
cells. We could also verify that the fusion peptide
P42-TAT has kept its protective properties and could
diffuse into the cells, targeting the different regions of
the brain and the different subcellular compartments.
This diffusion of P42-TAT will help to provide better
efficacy, preventing aggregate intercellular spreading for
instance [39]. In a second step, in order to enhance
the low stability and half time of P42-TAT and to enhance
its residence time in the CNS, we used the Aonys®
Figure 7 NP42T reduces the aggregate number in R6/2 model. R6/2 mice treated with the placebo generate a large number of Huntingtin
aggregates in the cortex (in red) (A, A’) and in the striatum (not shown). R6/2 mice treated with NP42T present a decreased number of aggregates in
the cortex (B, B’) and the striatum (not shown). The DAPI staining in grey (A’, B’) confirms that the number of cells remains identical. Pictures were
obtained by laser confocal microscopy (Zeiss LSM 780). The quantification shows that NP42T reduces the number (C, D), but not the size (E, F) of the
aggregates in both the cortex (C, E) and the striatum (D, F). Data represent means +/−SEM (n = 7 per group), and were analysed using Student’s t.test
(ns: not significant; ** p < 0.05).
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to deliver the fusion peptide. P42-TAT was formulated in
the water-in-oil microemulsion, allowing per mucosaladministrations and providing efficient delivery.
Therefore, the formulation named NP42T took the
advantages of these two delivery technologies. The
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represents the most appropriate and non-invasive route for
chronic peptide delivery. Using this technique, we verified
that P42-TAT is targeted to the brain as efficiently as when
provided directly by intra-cerebroventricular injection. We
also identified that P42 derivatives reside several hours in
the brain.
Per mucosal administration of NP42T in R6/2 mice
allowed early treatment starting at the second week.
Thus, we ensured the delivery of the peptide before the
first defects appearance. The treatment of R6/2 mice
with NP42T improved most of the HD symptoms when
administrated pre-symptomatically, delaying for instance
the motor impairment observed on rotarod test by
around 4 weeks. The benefits observed on the foot
clasping phenotypes were also notable until the animals
were sacrificed at week 11. For pathological markers,
such as aggregation or astrogliosis, the treatment
reduced their intensity. Notably, NP42T decreased the
number of the aggregates, but not their size. One
hypothesis is that by targeting hHtt exon1 [8], P42 might
interfere on both the nucleation and aggregation
processes, which might prevent new aggregates to
form. Note that because of exon1 self-interactions
[40], undoing aggregates is more difficult, which might
explain that when formed, the size of the aggregates keeps
unchanged. However, blocking the formation of new
aggregates may allow the neurons to eliminate the
preexisting inclusions and the soluble mutant Htt in
excess to recover normal functioning, as previously
mentioned [41]. Even though the exact role of aggregates
and their involvement in cell toxicity remain controversial
[42], we observed that the lower number of aggregates is
correlated with a recovery of different phenotypes, such as
motor performances for instance.
This raises the question concerning the efficiency of
P42 for post-symptomatic treatment. In 6 week-old R6/2
mice, most of the symptoms are already developed [24].
In these conditions, a late treatment revealed protective
effects on a range of phenotypes, but to a lower extent
(our unpublished results). This suggests that P42 might
not only target aggregate formation but could also interfere
on polyQ-Htt toxicity at other levels, which might delay
the progression of the disease.
In humans, the possibility of a pre-symptomatic test,
preceded by genetic counseling and carried out in accord-
ance with international recommendations, allows risky
subjects to assess their genetic status and to predict
whether a subject will develop HD, long before becoming
symptomatic [43]. Pre-symptomatic phase is a unique
opportunity for early intervention and neuroprotection, in
which our peptide could be proposed.
The microemulsion delivery mechanism is likely to
mediate a systemic distribution of P42-TAT in the wholeorganism. Even if the striatum and the cortex are the
most affected regions in HD, peripheral symptoms play
an important part in the quality of life, and eventually the
mortality of HD patients [37]. For instance, cardiovascular
defects are responsible for the death in 30% of the patients
[44]. For these reasons, whole body delivery of therapeutic
molecules seems more appropriate than a local administra-
tion (such as viral delivery in a limited region). Indeed, the
effect of NP42T on body weight could be explained by
more peripheral benefits. We investigated other peripheral
phenotypes such as heart mass, heart ventricle size and
glycaemia, but no clear variations were observed between
wild-type and R6/2 non-treated mice during the time of
our study (data not shown). The relatively short timing of
the study (from 2 to 11 weeks) and the use of a softer stock
of R6/2 mice could explain that we did not notice these
peripheral phenotypes previously described in other
reports [37]. Nevertheless, the effect of NP42T on body
weight evolution might be representative of an action on
muscle mass, metabolism, and food intake. Note that no
toxicity of P42-TAT has been noticed during this study,
since NP42T-treated wild-type mice developed normally,
and IC50 value on HeLa cell survival (MTT test) could
not be measured even in the presence of a large
excess of peptide. Moreover the number of neurons,
quantified after NeuN-immunostaining, was identical
in brains of wild-type mice treated by NP42T or
empty NP. Finally neither astrogliosis (detected by
GFAP-immunostaining- Figure 6), nor microglia activa-
tion (detected by IBA1-immunostaining- data not shown)
were identified in NP42T-treated wild-type brains.
The efficient rescue supported by P42 administration
represents one of the best therapeutic effects described
so far. Therapeutic research currently targets mutant
Htt at transcriptional or post-translational level. The
recent works in RNA interference or ASO strategies [45]
attempt to reduce the expression of the mutant
transcript. Despite recent progress, the limitation of this
approach lays in the effects on the wild-type allele
and the aggravation of the loss of function effects.
Biochemical molecules and intrabodies have also been
designed against the protein, in order to target abnormal
interaction and aggregation processes. In particular, a
range of molecules targeting directly the polyQ region of
the mutant Huntingtin, have been designed. For instance,
the peptide QBP1 and the molecule C2-8 bind the polyQ
region and reduce aggregation. These factors drove clear
effects in cell models [46,47], but rather mild effects in
R6/2 mouse model [14,15]. The combination of TAT with
transmucosal microemulsion delivery allowed us to use
particularly low doses of P42 (120 ug/week of peptide in
adult mice), comparative to what are usually used. In com-
parison, injection of 500 μg-2 mg/week of QBP1, fused to
TAT, had no effect on aggregation process in R6/2 mice,
Arribat et al. Acta Neuropathologica Communications 2014, 2:86 Page 15 of 17
http://www.actaneurocomms.org/content/2/1/86and only a slight effect on body weight [15]. Among the
drugs that target the polyQ-hHtt, C2-8 had the ability to
also reduce the aggregation process and to improve
rotarod performances of R6/2 mice, but this was obtained
only in presence of high doses of products (100 or
200 mg/kg/12 h) [14]. The direct targeting of polyQ
region might also provide unspecific action, especially if
using high doses. Indeed, a wide range of proteins, includ-
ing transcription factors, physiologically contain a polyQ
stretch, which is crucial for their activity, suggesting that
chronic treatment might lead to high toxicity. Hence, new
strategies that specifically target Huntingtin regions
flanking the polyQ have been tested. C4 and VL12.3
intrabodies, designed against the N17 region to inhibit
nucleation and aggregation, showed encouraging effects in
cell model [48,49], but only moderate improvements of
R6/2 mice [12]. Hence, the performances of NP42T
reported here in R6/2 mice should be greater in other HD
models. In particular, P42 effects on lifespan are partial
[8], and should be evaluated on less aggressive line.
In summary, P42 combines the specificity of intrabodies
targeting flanking regions, but resorts to natural molecular
mechanisms normally used by the cells. In addition, the
clear dose-effect of P42-TAT that we identified in cell
cultures, suggests that the doses that we administered
could be enhanced to provide greater benefit.
Conclusions
To conclude, this report highlights a clear therapeutic
potential of P42, a 23aa peptide, localized in endogenous
Huntingtin protein [8]. The action of this molecule was
potentiated through the combination of transmucosal
microemulsion delivery and CPP support. Such a strategy
could be applied more generally to other disorders, requir-
ing daily treatments. In early pre-symptomatic treatment,
NP42T is protective both on aggregation and on different
behavioural or physiological phenotypes. Because HD
is a genetic disorder, early screening for patients at
risk would enable pre-symptomatic treatment. Later
post-symptomatic administration of P42 in R6/2 mice
might also help to delay the progression of the disease,
but need to be tested further. Nevertheless our data
showed that P42 is clearly able to prevent the appearance
of symptoms, and to impede the progression of the
disease. To enhance the recovery of cell activity, a
treatment based on P42 should be combined with
other strategies to stimulate autophagic process or
proteasome activity for instance [50,51], but also in
bitherapies, associating for instance the lithium that
was also shown to be protective [30]. Because of the
aggressiveness of HD, it seems important to envisage a
synergic use of the different therapeutic ways. In this
context, P42 might represent one of the most powerful
tools to fight efficiently against mutant Huntingtin toxicity.Additional file
Additional file 1: Figure S1. MS/MS identification of the m/z 1801.84
peptide. The sequence is confirmed by the detection of numerous b-ions
(red arrows) and y-ions (green arrows) generated by the fragmentation of
the parent peptide. Figure S2. TAMRA-P42-TAT is able to diffuse into
C57BL/6 J mice brains. Females were injected into the right ventricle,
using ICV injection of 5 μg synthethic peptide. Six hours after the
injection, mice were sacrificed and brain sections monitored for TAMRA
signal (in red) using laser confocal microscopy Zeiss LSM 780. The
peptide fusion is efficiently internalized into the cells surrounding the
ventricle (A). Magnification shows that in the cells, TAMRA-P42-TAT is
localised in the nucleus and the cytoplasm, and is detected in the ciliary
structures (A’). The fusion peptide is able to reach both the ipsilateral and
controlateral cortex (B, magnification in B’). TAMRA-P42-TAT is also
massively detected in the neurons of the striatum (C) both in the nucleus of
the cells, and along the neurites (magnification in C’). The fusion peptide is
still detected when mice were sacrificed 24 hrs after ICV injection, and when
1 μg of TAMRA-P42-TAT was injected instead of 5 μg (data not shown).
Experiment were reproduced on several animals: n = 12.
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